Αρχική World News Breast Cancer Development Spurred on by Prolactin Hormone, Studies Show

Breast Cancer Development Spurred on by Prolactin Hormone, Studies Show

Most people know the hormone prolactin as the breastfeeding hormone, the one responsible for breast growth and development and the production of milk. However, a pair of recent studies have found that it may do much more than that.

Hormones contain proteins on their cell surface called receptors. These receptors receive and send biological messages that, in turn, regulate cell function. Each type of hormone, including prolactin, has its own special receptors that send different types of messages to keep our bodies functioning properly. However, hormones can sometimes be used against us and can help certain types of cancers grow and spread.

The studies, conducted at the Virginia Commonwealth University’s Massey Cancer Center and published in npj Breast Cancer, found strong evidence that prolactin may be a major contributor to the development of breast cancer.

Photo: Adobe Stock/karelnoppe

Article continues below

Our Featured Programs

See how we’re making a difference for People, Pets, and the Planet and how you can get involved!

Charles Clevenger, M.D., Ph.D., and his team discovered a new, altered form of the prolactin receptor which they believe directly drives breast cancer. They named the altered form of the hormone the human prolactin receptor intermediate isoform (hPRLrI).

The team noted that the modified version of the prolactin receptor interacted strangely with other forms of the receptor to turn benign breast cells into cancerous ones. The presence of hPRLrI in breast cancer cells, they found, was associated with triple-negative breast cancer, a particularly aggressive form of cancer. hPRLrI caused a rapid rate of cell reproduction and led to poor outcomes for patients.

“This research challenges the dogma that prolactin only functions in milk production and highlights the unique discovery that the hormone can contribute to breast cancer,” says Dr. Clevenger, associate director for precision oncology at Massey and Carolyn Wingate Hyde Endowed Chair in Cancer Research. “By understanding how the prolactin receptor correlates to breast cancer, novel therapeutic and prognostic agents can be developed to effectively treat the disease.”

Photo: Adobe Stock/PheelingsMedia

Researchers believe targeting drugs against the hPRLrI hormone receptors may help stave off the development of several types of recurrent breast cancers and keep tumors from growing quickly. This new knowledge, Dr. Clevenger hopes, will also someday inform more advanced diagnostic applications for breast cancer.

For now, Clevenger’s lab has been successful in substantially preventing tumor growth in preclinical models of ER-positive breast cancer. They used an HDAC6 inhibitor, a drug that blocks a protein associated with prolactin, to achieve this task.

Clevenger has also previously found success in a similar prolactin-related route. He deactivated Stat5, the genetic pathway that is responsible for the production of prolactin, in order to stunt breast cancer growth. Both the estrogen and prolactin receptors, therefore, appear to be able to cooperate through the activation of Stat5, which allows them to begin developing breast cancer.

Photo: Adobe Stock/salomonus_

“Global analysis of gene expression again revealed that prolactin is closely associated with breast cancer growth and could be subdued by treatment with an HDAC6 inhibitor,” says Dr. Clevenger.

The successful results of Dr. Clevenger’s studies show that he may be onto something with prolactin that could change the face of cancer treatment as we know it. In future studies, he hopes to develop and test cancer drugs that use prolactin as a primary target.

Provide Mammograms

Support those fighting Breast Cancer at The Breast Cancer Site for free!

Whizzco Source


Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Combining existing drugs improves prostate cancer survival

Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer that’s not spread elsewhere in the body. “Today’s results are the...

New Combination of Old Drugs Improves Survival in Patients with Prostate Cancer [ESMO Congress 2021 Press Release]

LBA4_PR - Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men...

Immunotherapy Prolongs Survival in Recurrent, Persistent or Metastatic Cervical Cancer [ESMO Congress 2021 Press Release]

LBA2_PR - Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase 3 KEYNOTE-826 study N. Colombo1, C....

Woman Diagnosed with Breast Cancer at 33 Launches Self-Examination App

Jessica Baladad has had a long history with self-examinations after a breast cancer scare in her early 20s. This habit helped save her life,...

Extended Adjuvant Treatment with Letrozole Results in Longer Survival in Postmenopausal Patients with Breast Cancer

According to results from a prospective, open-label, phase III study conducted in 69 Italian hospitals within the Gruppo Italiano Mammella among the postmenopausal patients...

Foodie Fridays: Apple Bok Choy Salad

While the temps may still be in the 80’s, apple season is upon us! Give this Apple Bok Choy salad a try!  It is...